TABLE 1.
Patient baseline characteristics.
| Erenumab (N = 108) | Fremanezumab (N = 90) | Control (N = 68) | |
|---|---|---|---|
| Female, n (%) | 92 (85) | 73 (81) | 53 (78) |
| Age (years), mean ± SD | 42.4 ± 12.5 | 44.5 ± 13.5 | 45.5 ± 9.9 |
| MMD baseline, mean ± SD | 14.0 ± 5.6 | 14.2 ± 6.3 | 14 ± 5.4 |
| MHD baseline, mean ± SD | 17.0 ± 6.2 | 17.2 ± 7.0 | 19.4 ± 5.7 |
| MAMD baseline, mean ± SD | 6.0 ± 3.6 | 5.4 ± 2.8 | 13.8 ± 5.9 |
| HADS‐D baseline, mean ± SD | 7.7 ± 4.5 | 7.9 ± 4.6 | 7.9 ± 4.3 |
| CES‐D baseline, mean ± SD | 19.9 ± 11.1 | 19.2 ± 10.5 | 18.6 ± 11.7 |
| Active depression, n (%) | 75 (70) | 55 (61) | 45 (66) |
Abbreviations: CES‐D, Center for Epidemiological Studies Depression Scale; HADS‐D, Hospital Anxiety and Depression Scale, Depression; MAMD, monthly acute medication days; MHD, monthly headache days; MMD, monthly migraine days.